New: SBC’s economic impact assessment report Read more
ReViral Appoints Brett Haumann as Chief Medical Officer
Published on 17 Jan 2022
Cell and Gene Therapy Catapult appoints Ian McCubbin OBE, CBE, as Chair of the Board
Published on 17 Jan 2022
Autolus Therapeutics announces retirement of chief financial officer and succession plan
Published on 10 Jan 2022
Freeline Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1
Published on 6 Jan 2022
Galecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business Officer
Published on 5 Jan 2022
SBC's James Latham co-opted to the Board at UKSPA
Published on 30 Dec 2021
Revolo Biotherapeutics announces the appointment of Tunde Otulana, M.D., to its Board of Directors
Published on 27 Dec 2021
Gyroscope Therapeutics to be Acquired for up to $1.5 Billion
Published on 22 Dec 2021
Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022
Published on 20 Dec 2021
Exploristics - investigation of an approved nebulised human Dnase enzyme (Pulmozyme) as a treatment for COVID-19
Published on 15 Dec 2021
Stevenage Bioscience Catalyst Wins Innovation Award 2021
Published on 13 Dec 2021
CGTC - New guidance on the development and marketing of ATMPs in the UK and EU in the post-BREXIT landscape
Published on 13 Dec 2021
Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial
Published on 13 Dec 2021
Report demonstrates Stevenage Bioscience Catalyst’s key role in delivering the economic benefit from leading edge UK life sciences
Published on 9 Dec 2021
LifeArc appoints first Chief Operating Officer
Published on 8 Dec 2021
New data shows cell and gene therapy industry creating new high value jobs and contributing strongly to opportunities across the UK
Published on 23 Nov 2021
Cell and Gene Therapy Catapult’s Annual Review 2021
Published on 22 Nov 2021
Biotech start-ups successfully graduate from DATA accelerator programme at Stevenage Bioscience Catalyst
Published on 18 Nov 2021
LifeArc unveils new strategy and £1.3 billion spend to drive life-changing science
Published on 16 Nov 2021
Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director
Published on 15 Nov 2021
LifeArc: New approach provides potential vaccine and treatment for Alzheimer’s
Published on 15 Nov 2021

Copyright © 2022 Stevenage Bioscience Catalyst

Designed and built by Onespacemedia

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.